Oramed Pharmaceuticals Inc. (ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that the United States Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug application(IND) for ORMD-0801, its oral insulin capsule.

"We are very pleased to have the FDA clearance to proceed," stated Nadav Kidron, CEO of Oramed. "The upcoming trial is a major milestone for Oramed and we look forward to continuing to progress ORMD-0801's clinical development in the US."

The NASDAQ OMX Group, Inc. (NDAQ) today announced that trading of Marketo, Inc. (MKTO), the provider of a leading cloud-based marketing software platform, commenced on The NASDAQ Stock Market on Friday, May 17, 2013. Marketo is listed under the ticker symbol MKTO.

Marketo is a provider of an easy-to-use marketing software platform that enables a variety of organizations to engage in modern relationship marketing. Marketo's customer base extends across more than 2,300 customers across a multitude of industries including business services, consumer, financial services, healthcare, manufacturing, media, technology and telecommunications.

Collaboration Expected to Fund more than $500 Million in Solar Projects, 110 Megawatts of Solar Capacity

SolarCity (SCTY), a leading provider of clean energy, today announced a lease financing agreement with Goldman Sachs (GS) to fund more than $500 million in solar power projects; an estimated 110 megawatts in generation capacity for homeowners and businesses.

The financing makes it possible for homeowners, businesses, government and other non-profit organizations to install solar panels with no upfront cost and pay less for clean, solar electricity than they currently pay for utility bills. The agreement was initiated in 2012 and expanded per its initial terms at the end of April.

Eagle Bulk Shipping Inc. (EGLE) today announced its results for the first quarter ended March 31, 2013. 

For the First Quarter:

Provides Important Foundation as Company Advances European Commercial Plans for ARIKACE to Treat Lung Infections in Cystic Fibrosis Patients

Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat patients battling serious lung diseases in orphan indications that are often life-threatening, today announced that the European Patent Office intends to grant E.U. Patent No. 1909759 for ARIKACE® (liposomal amikacin for inhalation). Once granted, the composition of matter patent provides exclusivity in any of the European Patent Office's member states where Insmed chooses to file at least through July 19, 2026. The Company's liposomal amikacin for inhalation is in clinical development to treat cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections and patients with nontuberculous mycobacteria (NTM) lung infections.

    First quarter homebuilding revenue of $11.4 million compared to $3.2 million last year     Net income from continuing operations of $1.1 million compared to net loss of $(1.4) million last year     Raising revenue outlook and reaffirming forecast for profitable 2013

Comstock Holding Companies, Inc. (CHCI) (“Comstock” or the “Company”), a homebuilding and multi-faceted real estate development and services company in the Washington, D.C. metropolitan area, today announced results for the first quarter of 2013, ended March 31.

Independent Bank Corp. (INDB), parent of Rockland Trust Company, and Mayflower Bancorp, Inc. (MFLR), parent of Mayflower Bank, have signed a definitive agreement for Independent to acquire Mayflower and Rockland Trust to acquire Mayflower Bank.

Mayflower Bank was founded in 1889 and currently has 8 Plymouth County bank branches, approximately $236 million in deposits, and approximately $141 million in loans.

“We are pleased to welcome Mayflower Bank customers and colleagues to Rockland Trust,” said Christopher Oddleifson, the Chief Executive Officer of Independent.

Synacor to Showcase Cloud ID Social Login with Google+ Sign-In for TV Everywhere Sites and Apps, Google I/O, May 15-17, Moscone West Convention Center, San Francisco, Calif.

Synacor Inc. (SYNC), the leading provider of next-gen startpages, award-winning TV Everywhere solutions, and cloud-based Identity Management (IDM) services, across multiple devices for cable, satellite, telecom and consumer electronics companies, will demo Cloud ID Social Login with Google+ and advanced TV Everywhere technologies in the Developer Sandbox at Google I/O, May 15-17, Moscone West Convention Center in San Francisco, Calif. Developers and technologists will discuss with Synacor how Social Login, recently named as a TMC Cable Spotlight Product of the Year, was built to break down TV Everywhere barriers, and how they can integrate similar technologies for their customers.

Nanosphere, Inc. (NASDAQ: NSPH)

Nanosphere, Inc. (NASDAQ: NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, announced today it has signed a distribution and collaboration agreement with Hitachi High-Technologies Corporation (Hitachi High-Tech). The agreement grants Hitachi High-Tech exclusive rights to market Nanosphere products in Japan. As well, the two companies intend to collaborate on assay and platform development.

Management to Host Conference Call Tomorrow, May 14, 2013 at 8:30AM ET

PDI, Inc. (PDII), today reported financial and operational results for the first quarter ended March 31, 2013. Summary financial and operating highlights include:

Theravance to receive $1.0 billion upfront payment upon closing; Elan to receive a 21% participation interest in potential future royalty payments associated with four respiratory programs

Theravance, Inc. (NASDAQ: THRX) and Elan Corporation, plc (NYSE: ELN) today announced that they have entered into a royalty participation agreement wherein Elan will purchase a participation interest in potential future royalty payments related to four respiratory programs partnered with GlaxoSmithKline plc (GSK): RELVAR™ ELLIPTA™/BREO™ ELLIPTA™, ANORO™ ELLIPTA™, MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist) monotherapy (GSK961081, or MABA '081), and vilanterol (VI) monotherapy. Under the terms of the agreement, Elan will make a one-time cash payment of $1.0 billion to Theravance in exchange for a 21% participation interest in the potential future royalty payments from the four programs when, as and if received by Theravance.

- Revenues of $22.1 million - Adjusted EBITDA - $2.8 million in Q1 2013 - Non-GAAP net income of $1.8 million in Q1 2013 Pointer Telocation Ltd. (Nasdaq CM: PNTR) - a leading developer, manufacturer and operator of Mobile Resource Management (MRM) and roadside assistance services for the automotive industry, announced today its financial results for the first quarter of 2013.

Financial Highlights

Revenues: Pointer's revenues for the first quarter of 2013 increased 2% to $22.1 million as compared to $21.6 million in the first quarter of 2012.

Dataram Corporation [NASDAQ: DRAM]), a leading international manufacturer of computer memory and software products, announced an expanded partnership with Advanced Micro Devices, Inc. (AMD) as described in a recent press release. This partnership includes Dataram Corporation as an AMD memory-manufacturing partner to produce AMD’s new Gamer Series memory. Dataram and AMD previously announced a formal agreement for Dataram to develop an AMD-branded version of Dataram’s popular RAMDisk software. Gamer Series memory is compatible with AMD and Intel platforms, supporting both AMP and XMP memory profiles. The memory is being sold and marketed under the AMD Radeon™ Memory brand, targeting gaming enthusiasts interested in exceptional memory performance and reliability.

Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS; ASX: UNS), a developer and supplier of injectable drug delivery systems, today announced its financial results for the quarter ended March 31, 2013, (the third quarter of Fiscal Year 2013).

Recent Highlights

Groundbreaking Results from University of California, San Francisco (UCSF) Clinical Validation Study Presented at American Urological Association (AUA) Annual Meeting First-of-its-Kind, Biopsy-Based Test Developed and Validated in Seven Studies Including More Than 1,100 Patients

Genomic Health, Inc. (GHDX) is making its Oncotype DX® prostate cancer test available to physicians and their patients today following the presentation by the University of California, San Francisco (UCSF) of a positive clinical validation study at the 2013 American Urological Association (AUA) Annual Meeting in San Diego. 

Adasuve® (loxapine) inhalation powder is approved in the U.S. for the acute treatment of agitation associated with schizophrenia and bipolar disorder

Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd (TEVA), and Alexza Pharmaceuticals, Inc. (ALXA) announced today that the companies have entered into an exclusive U.S. license and supply agreement for ADASUVE (loxapine) inhalation powder 10 mg for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Teva will be responsible for all U.S. commercial and clinical activities for ADASUVE, including U.S. post-approval clinical studies, and has gained rights to conduct additional clinical trials of ADASUVE for potential new indications in neurological disorders. Alexza will be responsible for manufacturing and supplying ADASUVE to Teva for commercial sales and clinical trials.

Total revenues increase 73% with significant increase in net income over prior year period Raises 2013 financial outlook to include total revenues of $330 million to $340 million, net income of $57 million to $64 million and non-GAAP adjusted earnings of $81 million to $91 million

Santarus, Inc. (SNTS), a specialty biopharmaceutical company, today reported financial and operating results for the quarter ended March 31, 2013.

Key financial results for the 2013 first quarter include:

* Gross Merchandise Volume of $1.6 Billion, Accelerating to 30% Growth in Local Currencies * Total Payments Volume of 532.1 Million, Accelerating to 62% Growth in Local Currencies * Net Revenues Grew to 102.7 Million, a 36% Growth in Local Currencies * Excluding the Non-Recurring Foreign Exchange Loss in Venezuela, Earnings Per Share During Q1'13 Would Have Been $0.53

MercadoLibre, Inc. (MELI) (http://www.mercadolibre.com), Latin America's leading e-commerce technology company, today reported financial results for the first quarter ended March 31, 2013.

Marcos Galperin, President and Chief Executive Officer of MercadoLibre, Inc., commented, "MercadoLibre was off to a good start in 2013. We saw volume accelerate across both our core marketplace and payments businesses, as we are meeting the growing demands of a quickly expanding base of users. Our ongoing initiatives are evidently raising the bar with respect to the ease, comfort and quality of the experience shoppers can expect as they make the transition to online shopping. We intend to keep driving this dynamic forward as the year advances."

Company Posts Revenue Increase, Returns to Profitability

Appliance Recycling Centers of America, Inc. (ARCI), a leading provider of appliance retailing and recycling services, today reported operating results for the first quarter ended March 30, 2013.

Total revenues increased 3.3% to $30.4 million versus $29.4 million for the first quarter of 2012. Overall, the Company reported consolidated net income of $0.2 million, or $0.03 per diluted share, compared with near-breakeven results in the first quarter of 2012.

Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE), is pleased to advise that it has executed an agreement with Three Rivers Provider Network, Inc. of Chula Vista, California, USA.

Three Rivers Provider Network ("TRPN") claims to be the largest supplemental PPO Network Foundation in the US, providing healthcare benefits to more than 10 million members, at more than 1 million locations nationwide.

The agreement with TRPN is the fifth such credentialing agreement executed between the Company and similar U.S. Preferred Provider Organisations ("PPOs") and increases the total number of covered lives, for which its BREVAGen™ test could be adjudicated as "in-network," to more than 23 million.